Estradiol

證據等級: L5

預測適應症: 10 個

Estradiol: From Unspecified Original Indication to Symptomatic Form of Fragile X Syndrome in Female Carrier

One-Sentence Summary

This evidence pack does not specify Estradiol’s original approved indication (data gap), and its mechanism of action is also not documented in the available data. The TxGNN model’s top-ranked prediction is Symptomatic Form of Fragile X Syndrome in Female Carrier, but this prediction is currently supported by zero clinical trials and zero publications — it is a model-only signal. Note: this evidence pack contains 10 ranked predicted indications for Estradiol; a second, better-evidenced candidate (anovulation) is summarised at the end of this report.

Quick Overview

Item	Content
Original Indication	Not specified in this evidence pack (data gap)
Predicted New Indication	Symptomatic form of fragile X syndrome in female carrier
TxGNN Prediction Score	98.76%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for Estradiol is not available in this evidence pack, and no verifiable direct mechanistic hypothesis links Estradiol to fragile X syndrome itself.

The only plausible connection identified is indirect: female carriers of the FMR1 premutation can develop fragile X-associated primary ovarian insufficiency (FXPOI) as a co-occurring reproductive-endocrine condition. This would, in principle, be a rationale for estrogen replacement in that co-occurring condition — but there is no literature or trial evidence that Estradiol affects the core cognitive or behavioural features of fragile X syndrome in carriers.

In short, this prediction rests on TxGNN’s model score alone. The mechanistic story is speculative and indirect, and no clinical or published evidence currently supports it.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (fragile X syndrome, female carriers) has no supporting clinical trials or literature, and the mechanistic link is indirect and unverified (L5, model prediction only).

To proceed, the following is needed:

Estradiol mechanism-of-action documentation
Original approved indication(s) for Estradiol (currently missing from this evidence pack)
TFDA/TGA-equivalent product information (warnings, contraindications) — currently a Blocking data gap
Preclinical or clinical data directly testing estrogen effects on fragile X syndrome symptoms (not just FXPOI-related ovarian function)

Other Predicted Indications in This Evidence Pack

This is a multi-indication candidate bundle (10 TxGNN predictions for Estradiol). Ranks 2–10, in order:

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation
2	Anovulation	98.58%	L2	Proceed with Guardrails
3	Ovarian remnant syndrome	98.58%	L4	Hold
4	Partial trisomy/tetrasomy, short arm of chromosome 18	98.56%	L5	Hold
5	Partial trisomy/tetrasomy, short arm of chromosome 12	98.56%	L5	Hold
6	Partial trisomy/tetrasomy, short arm of chromosome 5	98.54%	L5	Hold
7	Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement	98.52%	L5	Hold
8	Luteoma of pregnancy	98.47%	L4	Hold
9	Partial autosomal trisomy/tetrasomy	98.45%	L5	Hold
10	Ovarian ectopic pregnancy	98.44%	L4	Hold

Notable candidate — Anovulation (rank 2): unlike the top-ranked prediction, this indication is backed by a completed Phase 4 RCT (NCT03819140, OCP use in PCOS) and 20 related publications, reflecting Estradiol’s well-established, non-novel role (as part of combined oral contraceptives/HRT) in ovulation induction and endometrial preparation within assisted reproductive technology. Evidence level L2 — this is the strongest-evidenced prediction in the bundle and may warrant its own dedicated evaluation report if this is the direction of clinical interest.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.